¼¼°èÀÇ ±â´É¼º ¼ÒÈ­ºÒ·® Ä¡·áÁ¦ ½ÃÀå º¸°í¼­(2025³â)
Functional Dyspepsia Drug Global Market Report 2025
»óǰÄÚµå : 1730871
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,156,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 8,898,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,640,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

±â´É¼º ¼ÒÈ­ºÒ·® Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ °­·ÂÇÑ ¼ºÀåÀÌ Àü¸ÁµË´Ï´Ù. 2029³â¿¡´Â ¿¬°£ Æò±Õ ¼ºÀå·ü(CAGR) 6.6%·Î ¼ºÀåÇÒ Àü¸ÁÀ̸ç, 118¾ï ´Þ·¯·Î ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾ÈÀÇ ¼ºÀåÀº Æ÷°ýÀûÀÌ°í ¶óÀÌÇÁ½ºÅ¸ÀÏ¿¡ ±âÃÊÇÑ Á¢±Ù ¹æ½Ä¿¡ ´ëÇÑ ¼ÒºñÀÚ ±âÈ£ Áõ°¡, º´¿ë ¿ä¹ý¿¡ ´ëÇÑ ±âÈ£ Áõ°¡, ¶óÀÌÇÁ½ºÅ¸ÀÏ ¼öÁ¤ÀÇ Ã¤Åà Áõ°¡, Àå³úÃà¿¡ °üÇÑ ¿¬±¸ È®´ë, ºñ¾à¸®ÇÐÀû °³ÀÔÀÇ »ç¿ë Áõ°¡¿¡ ±âÀÎÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÀÌ ±â°£¿¡ ¿¹»óµÇ´Â ÁÖ¿ä µ¿ÇâÀ¸·Î´Â ¾àÁ¦ Á¦Çü Áøº¸, ÇコÄÉ¾î °ø±ÞÀÚ ¹× Á¦¾à±â¾÷ ¿¬°è, Á¤¹ÐÀÇ·á Á¢±Ù¹æ½ÄÀ¸·ÎÀÇ Àüȯ, ¿ø°ÝÀÇ·á ¹× µðÁöÅÐ Çコ±â¼úÀÇ ÅëÇÕ, °³º°È­ ÀÇ·á Àü·« µîÀ» µé ¼ö ÀÖ½À´Ï´Ù.

¾ËÄÚ¿Ã ¼Òºñ·® Áõ°¡°¡ ±â´É¼º ¼ÒÈ­ºÒ·® Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» ¹Ð¾î ¿Ã¸± °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¸ÆÁÖ, ¿ÍÀÎ, Áõ·ùÁÖ µîÀÇ À½·á¿¡ Æ÷ÇÔµÈ ¾ËÄÚ¿ÃÀº ¿¡Åº¿Ã·Î ±¸¼ºµÇ¾î ÀÖÀ¸¸ç ¼·Ãë ½Ã ÁßÃ߽Űæ°è¿¡ ¿µÇâÀ» ¹ÌÃÄ Áßµ¶ Áõ»óÀ» ÀÏÀ¸Å³ ¼ö ÀÖ½À´Ï´Ù. ¾ËÄÚ¿Ã ¼Òºñ Áõ°¡´Â, »çȸÀû ¹× ¹®È­Àû ¼ö¿ë, ½ºÆ®·¹½º ÇØ¼Ò, ÀÔ¼öÀÇ ¿ëÀ̼º, ¾ËÄÚ¿Ã À½·á ȸ»ç¿¡ ÀÇÇÑ Àû±ØÀûÀÎ ¸¶ÄÉÆÃ µîÀÇ ¿äÀο¡ ÀÇÇØ¼­ ÃÊ·¡µÇ°í ÀÖ½À´Ï´Ù. ±â´É¼º ¼ÒÈ­ºÒ·® Ä¡·áÁ¦´Â ¾ËÄڿ÷ΠÀÎÇÑ À§ÀÇ ºÒÆíÇÔÀ» ¿ÏÈ­Çϱâ À§ÇØ À§»ê ºÐºñ¸¦ ¾ïÁ¦ÇÏ°í ¼ÒÈ­ ±â´ÉÀ» °³¼±ÇÏ´Â ¸ñÀûÀ¸·Î »ç¿ëµË´Ï´Ù. ¿¹¸¦ µé¾î ¿µ±¹ Á¤ºÎ±â°üÀÎ OHID(Office for Health Improvement & Disparities)°¡ 2023³â 3¿ù ¹ßÇ¥ÇÑ º¸°í¼­¿¡ µû¸£¸é 2021-2022³â ¾ËÄڿÿ¡¸¸ °ü·ÃµÈ ÀÔ¿øÈ¯ÀÚ ¼ö´Â 34¸¸ 2,795¸íÀ¸·Î Àα¸ 10¸¸ ¸í´ç ÀÔ¿øÈ¯ÀÚ ¼ö´Â 626¸í¿¡ À̸£´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ÀÌó·³ ¾ËÄÚ¿Ã ¼Òºñ·®ÀÇ Áõ°¡°¡ ±â´É¼º ¼ÒÈ­ºÒ·® Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

´ë»ç¼º ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ±â´É¼º ¼ÒÈ­ºÒ·® Ä¡·áÁ¦ ½ÃÀåÀÇ È®´ë¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ´ë»çÀå¾Ö´Â ü³»ÀÇ Á¤»óÀûÀÎ ´ë»ç°úÁ¤ÀÌ È寮·¯Á® ¿µ¾ç¼Ò¿Í ¿¡³ÊÁö, ³ëÆó¹°ÀÇ Ã³¸®¿¡ ºÒ±ÕÇüÀÌ »ý±â¸é¼­ ¹ß»ýÇÕ´Ï´Ù. ½Ä»ýȰÀÇ È¥¶õ, ¾É±â ½¬¿î ¶óÀÌÇÁ ½ºÅ¸ÀÏ, À¯ÀüÀû ¼ÒÀÎ, ºñ¸¸À² »ó½Â µîÀÇ ¿äÀÎÀÌ ÀÌ·¯ÇÑ ÁúȯÀÇ À¯º´·ü »ó½Â¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ±â´É¼º ¼ÒÈ­ºÒ·® Ä¡·áÁ¦´Â ´ë»ç Àå¾Ö¸¦ °¡Áø »ç¶÷ÀÇ À§Àå Áõ»óÀ» °ü¸®ÇÏ°í ¼ÒÈ­ ±â´ÉÀ» °³¼±Çϱâ À§ÇØ »ç¿ëµË´Ï´Ù. ¿¹¸¦ µé¾î ¼¼°èº¸°Ç±â±¸(WHO)°¡ 2024³â 11¿ù ¹ßÇ¥ÇÑ º¸°í¼­¿¡ µû¸£¸é 2022³â¿¡´Â 18¼¼ ÀÌ»ó ¼ºÀÎÀÇ 14%°¡ ´ç´¢º´ Áø´ÜÀ» ¹Þ¾Ò½À´Ï´Ù. µû¶ó¼­ ´ë»ç¼º ÁúȯÀÇ À¯º´·ü »ó½ÂÀÌ ±â´É¼º ¼ÒÈ­ºÒ·® Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ ¹× Àü·«

Á¦4Àå ½ÃÀå-°Å½Ã°æÁ¦ ½Ã³ª¸®¿À ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°ÀÇ ¿µÇâ°ú ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼® ¹× Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº° ¹× ±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ ¹× ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å· ¹× ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹® ¹× Àü·«

Á¦36Àå ºÎ·Ï

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Functional dyspepsia drugs are a category of medications used to manage and relieve symptoms related to functional dyspepsia (FD), a gastrointestinal disorder marked by persistent or recurring upper abdominal discomfort without a clear structural or biochemical cause. These medications are designed to alleviate symptoms such as bloating, early satiety, nausea, and epigastric pain.

The primary types of drugs used to treat functional dyspepsia include proton pump inhibitors, H-2 receptor antagonists, antacids, antibiotics, prokinetics, and antidepressants. Proton pump inhibitors (PPIs) are a specific type of medication that reduce stomach acid production by inhibiting the action of the gastric proton pump (H+/K+-ATPase) in the stomach lining. These treatments are commonly used for functional dyspepsia as well as organic dyspepsia and are available through various distribution channels, including retail pharmacies, hospital pharmacies, and online pharmacies.

The functional dyspepsia drug market research report is one of a series of new reports from The Business Research Company that provides functional dyspepsia drug market statistics, including the functional dyspepsia drug industry's global market size, regional shares, competitors with a functional dyspepsia drug market share, detailed functional dyspepsia drug market segments, market trends and opportunities, and any further data you may need to thrive in the functional dyspepsia drug industry. This functional dyspepsia drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The functional dyspepsia drug market size has grown strongly in recent years. It will grow from $8.56 billion in 2024 to $9.15 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth during the historic period can be attributed to the increasing prevalence of various associated risk factors, higher healthcare expenditure, a rise in dyspeptic cases, a growing number of gastrointestinal disorders, and an expanding aging population.

The functional dyspepsia drug market size is expected to see strong growth in the next few years. It will grow to $11.80 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth during the forecast period can be attributed to the rising consumer preference for holistic and lifestyle-based approaches, a growing preference for combination therapies, increased adoption of lifestyle modifications, expanding research on the gut-brain axis, and a higher use of non-pharmacological interventions. Key trends expected in this period include advancements in drug formulation, collaborations between healthcare providers and pharmaceutical companies, a shift toward precision medicine approaches, the integration of telemedicine and digital health technologies, and personalized medicine strategies.

The increase in alcohol consumption is expected to boost the growth of the functional dyspepsia drug market. Alcohol, found in beverages such as beer, wine, and spirits, is composed of ethanol, which affects the central nervous system and can cause intoxication when consumed. The rising consumption of alcohol is driven by factors such as social and cultural acceptance, stress relief, easy availability, and aggressive marketing by alcoholic beverage companies. Functional dyspepsia drugs are used to alleviate alcohol-induced gastric discomfort by reducing acid production and improving digestive function. For example, a report published by the Office for Health Improvement & Disparities (OHID) in March 2023, a UK-based government agency, revealed that between 2021 and 2022, there were 342,795 hospital admissions related solely to alcohol, leading to a rate of 626 admissions per 100,000 people. Thus, the increase in alcohol consumption is contributing to the growth of the functional dyspepsia drug market.

The rise in the prevalence of metabolic disorders is expected to drive the expansion of the functional dyspepsia drug market. A metabolic disorder occurs when the body's normal metabolic processes are disrupted, leading to an imbalance in the processing of nutrients, energy, or waste. Factors such as poor diet, sedentary lifestyles, genetic predispositions, and rising obesity rates contribute to the growing prevalence of these disorders. Functional dyspepsia drugs are used to manage gastrointestinal symptoms and improve digestive function in individuals with metabolic disorders. For instance, a report published by the World Health Organization (WHO) in November 2024 stated that 14% of adults aged 18 and older were diagnosed with diabetes in 2022. Therefore, the rising prevalence of metabolic disorders is driving the growth of the functional dyspepsia drug market.

Leading companies in the functional dyspepsia drug market are focusing on clinical trials to develop innovative therapies that address the underlying causes of the condition, improve treatment effectiveness, and meet patient needs. Clinical trials are crucial for assessing the safety, efficacy, and optimal treatment strategies for functional dyspepsia drugs. For example, in December 2022, electroCore Inc., a US-based medical technology company, announced that the United States Patent and Trademark Office (USPTO) granted two patents for its innovative non-invasive vagus nerve stimulation (nVNS) technology. The first patent, U.S. Patent No. 11,511,109, covered a method for treating gastrointestinal disorders, including functional dyspepsia, using vagus nerve stimulation. The second patent, U.S. Patent No. 11,511,110, involved a system for delivering non-invasive electrical stimulation to the vagus nerve. These patents reinforced electroCore's position in advancing non-invasive neuromodulation therapies.

Major players in the functional dyspepsia drug market are Pfizer Inc., Abbvie Inc., Bayer AG, AstraZeneca plc, Astellas Pharma Inc., Eisai Co. Ltd., Menarini Group, Dr. Reddy's Laboratories Ltd., Lupin Limited, Daewoong Pharmaceutical Co. Ltd., Phathom Pharmaceuticals, Zeria Pharmaceutical Co. Ltd., Ironwood Pharmaceuticals Inc., Salix Pharmaceuticals Inc., RedHill Biopharma, RaQualia Pharma Inc., MetaMe Health, Renexxion LLC, Processa Pharmaceuticals, and Evoke Pharma Inc.

North America was the largest region in the functional dyspepsia drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in functional dyspepsia drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the functional dyspepsia drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The functional dyspepsia drug market consists of sales of mucosal protectants, neuromodulators, serotonin modulators, and herbal drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Functional Dyspepsia Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on functional dyspepsia drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for functional dyspepsia drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The functional dyspepsia drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Functional Dyspepsia Drug Market Characteristics

3. Functional Dyspepsia Drug Market Trends And Strategies

4. Functional Dyspepsia Drug Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Functional Dyspepsia Drug Growth Analysis And Strategic Analysis Framework

6. Functional Dyspepsia Drug Market Segmentation

7. Functional Dyspepsia Drug Market Regional And Country Analysis

8. Asia-Pacific Functional Dyspepsia Drug Market

9. China Functional Dyspepsia Drug Market

10. India Functional Dyspepsia Drug Market

11. Japan Functional Dyspepsia Drug Market

12. Australia Functional Dyspepsia Drug Market

13. Indonesia Functional Dyspepsia Drug Market

14. South Korea Functional Dyspepsia Drug Market

15. Western Europe Functional Dyspepsia Drug Market

16. UK Functional Dyspepsia Drug Market

17. Germany Functional Dyspepsia Drug Market

18. France Functional Dyspepsia Drug Market

19. Italy Functional Dyspepsia Drug Market

20. Spain Functional Dyspepsia Drug Market

21. Eastern Europe Functional Dyspepsia Drug Market

22. Russia Functional Dyspepsia Drug Market

23. North America Functional Dyspepsia Drug Market

24. USA Functional Dyspepsia Drug Market

25. Canada Functional Dyspepsia Drug Market

26. South America Functional Dyspepsia Drug Market

27. Brazil Functional Dyspepsia Drug Market

28. Middle East Functional Dyspepsia Drug Market

29. Africa Functional Dyspepsia Drug Market

30. Functional Dyspepsia Drug Market Competitive Landscape And Company Profiles

31. Functional Dyspepsia Drug Market Other Major And Innovative Companies

32. Global Functional Dyspepsia Drug Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Functional Dyspepsia Drug Market

34. Recent Developments In The Functional Dyspepsia Drug Market

35. Functional Dyspepsia Drug Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â